Introduction {#s1}
============

Lung function, specifically forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV~1~), are objectively measurable quantitative parameters of respiratory health. It is an early indicator of respiratory and systemic inflammation, and associated with cardiorespiratory morbidity and mortality. Acute effects of air pollution on lung function at levels currently observed in Western Europe at all ages are well established. To what extent long-term exposure to air pollution results in lower lung function remains less clear \[[@C1]\]. Evidence for long-term pollution effects on slowing down lung function growth in children is strong, while data for chronic lung function effects in adults is more limited and mostly restricted to susceptible populations \[[@C1]--[@C3]\]. In the largest of the predominantly cross-sectional studies \[[@C4]--[@C7]\], F[orbes]{.smallcaps} *et al.* \[[@C4]\] found increases in 10 μg·m^−3^ of particulate matter of size 10 μm or less (PM~10~) associated with a decrease of about 3% in FEV~1~. At first spirometry SAPALDIA found an increase of 10 μg·m^−3^ in annual mean concentration of PM~10~ was associated with 3.4% lower FVC and 1.6% lower FEV~1~ \[[@C5]\]. The SALIA study of females showed negative associations of PM~10~ concentrations with FEV~1~ and FVC (5.1% and 3.7% respectively, per 7 μg·m^−3^ 5-year annual mean PM~10~) \[[@C7]\]. The strongest indirect evidence for adverse long-term pollution effects on lung function decline in adults comes from a single follow-up study demonstrating that improvements in PM~10~ exposure over a period of 11 years attenuated the age-related decrease in respiratory function \[[@C8]\]. A more recent study found cumulative long-term exposure to ambient PM~10~ and ozone associated with both FEV~1~ and FVC decline in an elderly population and suggested an increased susceptibility among frail persons \[[@C9]\]. Statistically significant associations were also reported for NO~2~ and traffic exposure \[[@C5], [@C7]\].

The ESCAPE project (European Study of Cohorts for Air Pollution Effects) combined data from over 30 cohort studies and modelled home outdoor levels of air pollution in a standardised manner \[[@C10]\]. This paper makes use of five health cohorts with spirometry data, to investigate the association of air pollution with lung function level and age-related decline.

Methods {#s2}
=======

Design and participants {#s2a}
-----------------------

This study is an analysis of cohort data obtained by ESCAPE to investigate the long term effects of exposure to air pollution on respiratory health in Europe and a meta-analysis of the cohort specific results. The present study included five European cohorts/studies from eight countries with information on lung function and the most important potential confounders. The analyses were based on subpopulations from the European Community Respiratory Health Survey (ECRHS), French Epidemiological study on Genetics and Environment of Asthma (EGEA), the National Survey of Health and Development (NSHD), Study on the influence of Air pollution on Lung function, Inflammation and Aging (SALIA) and Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) (online supplementary material (methods: cohorts section) and supplementary table S1). Criteria for inclusion of cohort participants in the present analyses were: age of at least 20 years; pre-bronchodilation spirometry data from two different time points approximately one decade apart (referred to as first and second spirometry, respectively); non-missing information for the primary covariates used in the main models (questionnaire-based variables: age, sex, smoking status, education; measured variables: height and BMI (derived from measured height and weight)); living in cohort areas selected for ESCAPE monitoring campaigns; and successfully assigned home outdoor exposure estimates for NO~2~/NO~x~/traffic indicators (referred to as NO-population) and PM metrics (a subsample of the NO population, referred to as PM-population). Of 13 259 participants with first and second spirometry living in ESCAPE monitoring areas, 7615 and 4233, respectively provided complete datasets towards analysis of NO~2~/NO~x~/traffic indicators and PM metrics (supplementary figure S1). All included cohort studies were approved by the institutional medical ethics committees and undertaken in accordance with the Declaration of Helsinki. Each cohort study followed the rules for ethics and data protection set up in the country in which they were based.

Exposure data {#s2b}
-------------

ESCAPE exposure assessment has been described previously, and is based on fully standardised measurement and modelling protocols ([www.escapeproject.eu/manuals/](www.escapeproject.eu/manuals/)) \[[@C10]--[@C13]\]. The general concept consisted in the individual assignment of outdoor annual mean concentrations of a pre-defined set of air pollution markers to each participant\'s residential address.

ESCAPE monitoring campaigns in different study areas between 2008 and 2011 measured NO~2~ and NO~x~ as well as, in a smaller number of areas PM~2.5~, PM~10~, the coarse fraction of PM (PM~10~ minus PM~2.5~) and light absorbance of PM~2.5~. Within each study area, concentration levels were monitored at 40 (NO~2~, NO~x~) or 20 (PM measures) predefined sites during three seasonally distinct 2-week periods \[[@C13], [@C14]\]. Land use regression (LUR) models were developed to explain the spatial variation of measured annual average air pollutant concentration within each study area. This technique combines measurement data with Geographic Information System (GIS) derived land-use and traffic information to predict annual pollution concentration at sites without measurements and was used to estimate annual pollutant concentrations at each participant\'s residential address \[[@C10], [@C11]\].

In addition to pollutant concentrations, we also used as indicators of local exposure to traffic related pollutants, traffic intensity at the road nearest to a participant\'s home and total traffic load on major roads in a 100-m buffer of the home. Traffic measures were often used in other studies as proxies of exposure to near-road pollutants, such as ultrafine particles or NO, which exponentially decay within 100--150 m from the curb side.

To address the time discrepancy between air pollution monitoring (2008--2011) and health examination (spirometry conducted between 1985--2010; supplementary table S2), sensitivity analyses replaced ESCAPE exposure estimates with estimates back extrapolated to the time of first and second spirometry (except for the time of first spirometry in ECRHS and EGEA, where no historical data was available, and of second spirometry in NSHD and SALIA conducted between 2006 and 2010, sufficiently close to the ESCAPE monitoring campaigns). During the past decades, air quality has in general improved. Given the lack of historic LUR models, ESCAPE could not individually estimate within-city contrasts of air quality for these past years. Instead, where available, annual means from fixed site monitoring stations were used to derive past annual mean concentrations for pollutants with available historic data (NO~2~ and PM~10~ only). For each study participant\'s home address the back extrapolated concentration was obtained by multiplying the modelled ESCAPE annual mean concentration with the ratio between average annual concentrations as derived from the routine monitoring site(s) for the period in the past and for the ESCAPE measurement period time (details can be found in [www.escapeproject.eu/manuals/](www.escapeproject.eu/manuals/)) \[[@C12]\]. The procedures applied assumed that the within-city spatial contrasts remained proportional over time. G[ulliver]{.smallcaps} *et al.* \[[@C15]\] confirmed the validity of this assumption for the UK.

Lung function metrics and outcomes {#s2c}
----------------------------------

FEV~1~ and FVC were used as outcome metrics. In cross-sectional analysis, we focused on lung function measured at the second spirometry (time point closest to ESCAPE air pollution monitoring). Change in lung function between first and second spirometry was assessed as both annual lung function change (mL·year^−1^) and annual change in lung function as a percentage of the first spirometry value (%·year^−1^) (supplementary material; methods: lung function metrics and outcomes section), with a negative value representing a decline. Data presented are restricted to absolute change as results did not materially differ for percent change as outcome.

Statistical analyses {#s2d}
--------------------

First, study specific data were analysed separately following identical analytical procedures. Associations of air pollutants with lung function metrics were estimated using multivariable mixed linear regression models with a random intercept for ESCAPE areas with their own exposure monitoring and modelling. Three confounder models were specified *a priori*, adjusting for an increasing number of covariates selected on the basis of previous cohort studies of air pollution and lung function and the availability of data for most cohorts, excluding missing values on any of the covariates. The covariate definitions were standardised across studies (supplementary material; methods section). In the absence of materially different effect estimates derived from models adjusting for additional covariates, we chose as main analytic model the one adjusting for age (years), age squared, height (cm), sex, body mass index (BMI; kg·m^−2^), educational level (low as reference, medium, high), and smoking status (never as reference, ever). Models analysing traffic exposure indices were additionally adjusting for background NO~2~ concentrations. The traffic indicator coefficients are thus assumed to reflect the impact of pollutants highly concentrated along the roads. The median of traffic indicator values across all studies was chosen as cut-off for dichotomising the continuous traffic exposure (≤5000 and \>5000 cars per day for traffic intensity on the nearest major road; ≤500 and \>500 car-km driven per day for the traffic intensity on major roads in a 100 m buffer) (supplementary material; methods: statistic models section). Traffic variables were also analysed on a continuous scale but this did not produce meaningful results.

Secondly, cohort-specific overall and stratum-specific effect estimates obtained by mixed linear regression models were meta-analysed (supplementary material; methods: meta-analysis section).

A pre-defined set of variables considering previous evidence and cohort differences was tested for effect modification. We compared the summary estimates of the two opposite subgroups (females *versus* males; not obese *versus* obese; never *versus* ever smokers; never asthma *versus* ever asthma) using a chi-square test with one degree of freedom. In sensitivity analyses we restricted the analytical model to non-movers and participants aged ≥30 years (age at first spirometry).

A standardised analytical approach was used to minimise the possibility of differential bias across participating cohorts. We controlled for different known or potential individual confounding factors in our analyses. Moreover, we included random effects for the different cohort areas to adjust for geographic clustering of outcomes. Additionally, we performed several sensitivity analyses in selected subsamples to address specific potential biases (*e.g.* in the subsample of non-movers to address potential bias due to health-related changes in exposure).

Statistical analyses were performed using STATA, version 12 (Stata Statistical Software, Release 12; StataCorp., College Station, TX, USA).

Results {#s3}
=======

Study characteristics {#s3a}
---------------------

[Table 1](#TB1){ref-type="table"} provides a description of the cohort specific study populations. The average age of the cohorts at the time of second spirometry ranged from 43 years (ECRHS) to 73 years (SALIA). The SALIA population, consisting exclusively of females, exhibited the lowest mean levels of FEV~1~ (2.20 L) and FVC (2.91 L) ([table 1](#TB1){ref-type="table"}) (for the smaller PM subpopulation and for the cohort-specific lung function distributions stratified by sex, smoking and asthma status, refer to supplementary table S3).

###### Description of cohort-specific study populations

  ------------------------------------------------------------ -------------- -------------- -------------- -------------- --------------
                                                                 **ECRHS**       **EGEA**       **NSHD**      **SALIA**     **SAPALDIA**
  **Total n**                                                       3859           568            844            580            1764
  **First spirometry**                                           1991--1993     1991--1995        1999        1985--1994     1991--1992
  **Second spirometry**                                          2001--2002     2003--2007     2006--2010     2007--2009        2002
  **Female**                                                    1981 (51.3)     303 (53.3)     471 (55.8)    580 (100.0)     980 (55.6)
  **Age years**                                                   43.0±7.2      53.1±11.3       63.3±1.1       73.3±3.4      53.2±11.0
  **BMI kg·m^−2^**                                                25.7±4.6       25.3±4.3       27.7±4.9       27.4±4.5       25.4±4.3
  **Height cm**                                                  168.6±9.5      168.5±8.4      167.4±8.6      162.3±5.5      168.8±9.0
  **Ex-smoker**                                                 1064 (27.6)     206 (36.3)     497 (58.9)     99 (17.1)      568 (32.2)
  **Current smoker**                                            1224 (31.7)     81 (14.3)       77 (9.1)       18 (3.1)      492 (27.9)
  **Pack years at first spirometry^\#^**                          7.7±12.0       5.9±10.0       9.1±12.6       2.8±8.4       10.9±17.9
  **Pack years from first to second  spirometry^\#^**             3.9±10.9       1.7±8.3        0.7±2.5        0.6±6.7        3.1±6.5
  **Medium educational level^\#^**                              1321 (34.2)     118 (20.8)     439 (52.0)     276 (47.6)    1121 (63.5)
  **High educational level^\#^**                                1420 (36.8)     263 (46.3)     102 (12.1)     199 (34.3)     520 (29.5)
  **Environmental tobacco exposure at  home or at work^\#^**     676 (17.5)     233 (41.0)     168 (19.9)     347 (59.8)     119 (6.7)
  **Occupational exposure to  dust/fumes or gases^\#^**         1685 (43.7)     125 (22.0)     246 (29.1)      39 (6.7)      460 (26.1)
  **Ever asthma^\#,¶^**                                          616 (16.0)     183 (32.2)      83 (9.8)       50 (8.6)      155 (8.8)
  **FEV~1~ L**                                                   3.47±0.81      3.03±0.85      2.83±0.66      2.20±0.42      3.10±0.82
  **FVC L**                                                      4.33±1.00      4.00±1.01      3.57±0.81      2.91±0.54      4.08±1.02
  **FEV~1~ change^+^ L**                                        −0.026±0.032   −0.028±0.031   −0.022±0.025   −0.020±0.014   −0.033±0.030
  **FVC change^+^ L**                                           −0.018±0.040   −0.015±0.037   −0.025±0.034   −0.022±0.019   −0.022±0.041
  ------------------------------------------------------------ -------------- -------------- -------------- -------------- --------------

Data are presented as mean±[sd]{.smallcaps} for continuous variables, or n (%) for categorical variables, unless otherwise stated. Characteristics refer to time point of second spirometry, and are presented for the larger subgroup of participants included in the analysis of NO~2~ and NO~x~ and traffic indicators (characteristics for the smaller subgroup of participants included in the particulate matter metrics analyses are presented in supplementary table S1). BMI: body mass index; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity. ^\#^: information missing on a limited number of subjects; ^¶^: asthma diagnosed by a physician at first and/or at second spirometry; ^+^: change in lung function between first and second spirometry.

Air pollution exposure {#s3b}
----------------------

Table [2](#TB2){ref-type="table"} shows the distribution of the air pollution metrics for each study area. Variance explained by LUR models varied between 55% and 92% for NO~2~ and between 68% and 90% for PM~10~ (supplementary table S4). Mean exposure was lowest for all air pollution metrics in NSHD. Within-study contrasts were smallest for SALIA and SAPALDIA, reflecting the restricted geographic region covered (supplementary table S5). The study specific correlations between the exposure metrics were generally highest between NO~2~ and NO~x~ (rho of 0.90--0.98), but moderate to low between pollutants and traffic indicators (supplementary table S6). ESCAPE derived exposures were highly correlated with the exposures back-extrapolated to the time of the second spirometry (rho(NO~2~) ≥ 0.94; rho(PM~10~) ≥0.91), but less strongly correlated with exposures back-extrapolated to the first spirometry (0.56 ≤ rho(NO~2~) ≤ 0.92; 0.47 ≤ rho(PM~10~) ≤ 0.74).

###### Distribution of all exposure estimates (annual averages of ambient air pollutants and traffic indicators), at participants residential addresses in each cohort

  ------------------------------------------------------------- ----------- ---------- ---------- ----------- -------------- ------- ---------- --------- ------- ---------- --------- ------- ---------- --------- ------
  **Exposures**                                                  **ECRHS**   **EGEA**   **NSHD**   **SALIA**   **SAPALDIA**                                                                                         
  **N**                                                          **Mean**    **IQR**     **N**     **Mean**      **IQR**      **N**   **Mean**   **IQR**   **N**   **Mean**   **IQR**   **N**   **Mean**   **IQR**  
  **PM~2.5~ μg·m^−3^**                                             1830        15.9       7.0         342          15.3        2.0      751        9.5      1.5      580       17.8      1.7      729       16.8     1.1
  **PM~2.5~ absorbance ×10^−5^ m^−1^**                             1540        2.0        1.6         148          2.1         1.3      751        1.0      0.3      580        1.4      0.4      729        1.9     0.5
  **PM~10~ μg·m^−3^**                                              1830        25.8       9.7         342          25.1        4.0      751       15.7      1.9      580       26.7      2.1      729       23.2     2.3
  **Coarse PM^\#^ μg·m^−3^**                                       1830        10.3       4.7         342          9.4         3.3      751        6.4      0.8      580        9.4      1.6      729        6.5     1.9
  **NO~2~ μg·m^−3^**                                               3859        28.9       18.7        568          27.4       14.7      844       22.4     10.0      580       27.6      8.1      1764      27.0     7.7
  **NO~x~ μg·m^−3^**                                               3859        50.5       34.5        568          46.7       27.9      844       37.5     17.1      580       44.2     20.7      1764      44.8     15.2
  **Traffic intensity on nearest road^¶^**                         2492        4807       5509        568          6633       6667      844       1239       0       580       1642       0       1697      3207     3876
  **Traffic load on nearest major  road^+^**                       2687        1.45       1.67        568          1.37       1.58      844       0.27       0       580       0.72     0.32      1671      0.94     1.42
  **NO~2~ back-extrapolated to first  spirometry μg·m^−3^**        NA^§^      NA^§^      NA^§^       NA^§^        NA^§^       NA^§^     841       26.3     11.2      580       36.0     14.0      1762      47.7     12.3
  **PM~10~ back-extrapolated to first  spirometry μg·m^−3^**       NA^§^      NA^§^      NA^§^       NA^§^        NA^§^       NA^§^     748       22.0      2.6      580       47.7     13.6      726       46.2     4.0
  **NO~2~ back-extrapolated to second  spirometry μg·m^−3^**       3859        34.2       23.0        568          32.1       17.5     NA^ƒ^      NA^ƒ^    NA^ƒ^    NA^ƒ^      NA^ƒ^    NA^ƒ^     1764      31.0     8.0
  **PM~10~ back-extrapolated to  second spirometry μg·m^−3^**      1388        27.1       8.4         148          27.0        5.3     NA^ƒ^      NA^ƒ^    NA^ƒ^    NA^ƒ^      NA^ƒ^    NA^ƒ^     729       37.8     4.3
  ------------------------------------------------------------- ----------- ---------- ---------- ----------- -------------- ------- ---------- --------- ------- ---------- --------- ------- ---------- --------- ------

IQR: interquartile range; PM~2.5~: particulate matter with a diameter of ≤2.5 μm; PM~10~: particulate matter with a diameter of ≤10 μm. ^\#^: fraction of PM~2.5~ to relative to PM~10~; ^¶^: cars per day; ^+^: traffic load on nearest major road within a 100 m buffer presented in thousands of car-km driven per day; ^§^: no complete exposure back-extrapolation to first spirometry available; ^ƒ^: no back-extrapolation applied as time point of second spirometry coincides with time point of ESCAPE monitoring campaign.

Association between air pollution and lung function {#s3c}
---------------------------------------------------

The main meta-analysis results for associations of each air pollution metric with level and change of lung function are presented in table [3](#TB3){ref-type="table"}. No associations between any exposure metric and lung function decline were present, irrespective of covariate adjustment and subgroup (sex, obesity, asthma and smoking). Looking at levels of lung function cross-sectionally, we found higher NO~2~ and NO~x~ exposures to be associated with lower levels of FVC and FEV~1~. An increase of 10 μg·m^−3^ in NO~2~ exposure was associated with a −14.0 mL lower level of FEV~1~ (95% CI −25.8-- −2.1) and −14.9 mL lower level of FVC (95% CI −28.7-- −1.1) ([table 3](#TB3){ref-type="table"}, [figs 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). An increase of 20 μg·m^−3^ in NO~x~ exposure was associated with a lower level of FEV~1~, by −12.9 mL (95% CI −23.87-- −2.0) and of FVC, by −13.3 mL (95% CI −25.9-- −0.7) and an increase of 10 μg·m^−3^ in PM~10~ was associated with a lower level of FEV~1~ (−44.6 mL, 95% CI −85.4-- −3.8) and FVC (−59.0 mL, 95% CI −112.3-- −5.7) (table [3](#TB3){ref-type="table"}). The other PM metrics were not associated with lung function level. Higher traffic load on major roads in a 100 m buffer from residential address was associated with lower levels of FEV~1~ (−32.34 mL, 95% CI −59.30-- −5.38).

![Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO~2~ with level of forced expiratory volume in 1 s (FEV~1~; in mL) (based on all study participants living in sites with ESCAPE models available). NO2_1 indicates NO~2~ measured at time of ESCAPE. Associations with lung function measures are presented as increments in NO~2~ per 10 μg·m^−3^. I-square: variation in estimated effects attributable to heterogeneity. D+L (Der Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were adjusted for: age, age squared, height, sex, body mass index, highest educational level, and smoking status at second spirometry; negative estimates indicated lower lung function with increasing exposure. ES: effect size.](ERJ-01300-2014.01){#F1}

![Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO~2~ with level of forced vital capacity FVC; in mL) (based on all study participants living in sites with ESCAPE models available). NO~2~\_1 indicates NO~2~ measured at time of ESCAPE. Associations with lung function measures are presented as increments in NO~2~ per 10 μg·m^−3^. I-square: variation in estimated effects attributable to heterogeneity. D+L (Der Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were adjusted for: age, age squared, height, sex, body mass index, highest educational level, and smoking status at second spirometry; negative estimates indicated lower lung function with increasing exposure. ES: effect size.](ERJ-01300-2014.02){#F2}

###### Results of meta-analyses for the association between level and change of lung function and exposure to air pollution and traffic intensity indicators

  ------------------------------------------------------------------------------ ------------------------------------------- ----------------- --------------------------- -------------- ------------------ ---------------------------
  **Exposure (increment)**                                                           **Level of lung function (mL)^\#^**                                                                                     

                                                                                                 **FEV~1~**                       **FVC**                                                                    

                                                                                                 **Beta^¶^**                    **95% CI**            **I^2\ §^**\          **Beta^¶^**       **95% CI**            **I^2\ §^**\
                                                                                                                                                    **p-value (het)**                                             **p-value (het)**

  **NO~2~ (10 μg·m^−3^)**                                                                          −13.98                     −25.82 to −2.14             0.0%\                −14.93      −28.73 to −1.13              0.0%\
                                                                                                                                                         p=0.625                                                       p=0.977

  **NO~x~ (20 μg·m^−3^)**                                                                          −12.91                     −23.79 to −2.04             0.0%\                −13.25      −25.85 to −0.65              0.0%\
                                                                                                                                                         p=0.861                                                       p=0.962

  **PM~10~ (10 μg·m^−3^)**                                                                         −44.56                     −85.36 to −3.76             0.0%\                −58.96      −112.27 to −5.65             0.0%\
                                                                                                                                                         p=0.628                                                       p=0.785

  **PM~2.5~ (5 μg·m^−3^)**                                                                         −21.14                     −56.37 to 14.08             0.0%\                −36.39      −83.29 to 10.50              0.0%\
                                                                                                                                                         p=0.535                                                       p=0.877

  **PM~2.5~ absorbance (1×10^−5^ m^−1^)**                                                          −24.40                     −55.58 to 6.79              0.0%\                −12.94      −50.23 to 24.30              0.0%\
                                                                                                                                                         p=0.709                                                       p=0.619

  **Coarse PM (5 μg·m^−3^)**                                                                       −22.36                     −94.00 to 49.27            12.6%\                 2.88       −87.85 to 93.60              0.0%\
                                                                                                                                                         p=0.333                                                       p=0.760

  **Traffic intensity on nearest road (high/low)^ƒ,\#\#^**                                         −27.61                     −59.62 to 4.39             29.0%\                −10.37      −48.23 to 27.49             27.3%\
                                                                                                                                                         p=0.228                                                       p=0.239

  **Traffic load on nearest major road in a 100-m buffer (high/low)^\#\#,¶¶^**                     −32.34                     −59.30 to −5.38             0.0%\                −18.64      −50.22 to 12.94              0.0%\
                                                                                                                                                         p=0.784                                                       p=0.967

                                                                                                                                                                                                             

  **Exposure (increment)**                                                        **Change in lung function (mL per year)**                                                                                  

                                                                                                 **FEV~1~**                       **FVC**                                                                    

                                                                                                **Beta^§§^**                    **95% CI**      **I^2\ §^ p-value (het)**   **Beta^§§^**      **95% CI**      **I^2\ §^ p-value (het)**

  **NO~2~ (10 μg·m^−3^)**                                                                           0.30                       −0.39 to 0.98              0.0%\                 0.02        −0.84 to 0.88               0.0%\
                                                                                                                                                         p=0.681                                                       p=0.532

  **NO~x~ (20 μg·m^−3^)**                                                                           0.18                       −0.44 to 0.80              0.0%\                −0.09        −0.86 to 0.69               0.0%\
                                                                                                                                                         p=0.708                                                       p=0.804

  **PM~10~ (10 μg·m^−3^)**                                                                          −0.39                      −2.85 to 2.06             53.1%\                −1.42        −4.53 to 1.70              28.4%\
                                                                                                                                                        p=0.074%                                                       p=0.232

  **PM~2.5~ (5 μg·m^−3^)**                                                                          −0.14                      −2.26 to 1.98             23.8%\                −1.37        −4.04 to 1.29               0.0%\
                                                                                                                                                         p=0.263                                                       p=0.964

  **PM~2.5~ absorbance (1×10^−5^ m^−1^)**                                                           0.88                       −0.76 to 2.52             54.5%\                 1.14        −0.95 to 3.24               4.5%\
                                                                                                                                                         p=0.066                                                       p=0.381

  **Coarse PM (5 μg·m^−3^)**                                                                        0.26                       −3.92 to 4.43             61.7%\                −1.31        −6.49 to 3.88               0.0%\
                                                                                                                                                         p=0.034                                                       p=0.506

  **Traffic intensity on nearest road (high/low)^ƒ,\#\#^**                                          −0.74                      −2.58 to 1.10              0.0%\                −0.15        −2.49 to 2.18              18.1%\
                                                                                                                                                         p=0.772                                                       p=0.299

  **Traffic load on nearest major road in a 100-m buffer (high/low)^\#\#,¶¶^**                      −0.32                      −1.81 to 1.18              0.0%\                 0.34        −1.56 to 2.25               0.0%\
                                                                                                                                                         p=0.987                                                       p=0.672
  ------------------------------------------------------------------------------ ------------------------------------------- ----------------- --------------------------- -------------- ------------------ ---------------------------

FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; PM: particulate matter. ^\#^: level of lung function for cross-sectional analysis was derived from second spirometry. ^¶^: the beta values for the association between level of lung function and exposure are adjusted for age, age squared, height, sex, body mass index (BMI), highest educational level, and smoking status at second spirometry; a negative sign indicates lower lung function with increasing exposure. ^§^: I^2^ and Cochran\'s test for heterogeneity of effect estimates between cohorts. ^ƒ^: low traffic intensity on nearest road: ≤5000 cars per day; high: \>5000 cars per day. ^\#\#^: associations with traffic intensity (high/low) and traffic load (high/low) were additionally adjusted for background NO~2~ concentrations. ^¶¶^: low traffic load on the nearest major road in a 100-m buffer: ≤500 car-km driven per day; high: \>500 car-km driven per day. ^§§^: the beta values of the association between change in lung function and exposure are adjusted for sex, age and height at first spirometry, highest educational level, smoking at first spirometry, smoking cessation and change in BMI to the second spirometry; a negative sign indicates steeper lung function decline with increasing exposure.

Associations observed for NO~2~ and PM~10~ with FEV~1~ and FVC at second spirometry remained largely unaltered when ESCAPE exposure estimates of NO~2~ and PM~10~ in ECRHS, EGEA and SAPALDIA were replaced with NO~2~ and PM~10~ estimates back-extrapolated to the time point of the second spirometry. The inverse association between PM~10~ and FVC became stronger and statistically significant (supplementary table S7).

In subgroup analysis, the NO~2~ and NO~x~ (data not shown) associations with FEV~1~ and FVC were particularly observed in obese participants (FEV~1~: figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}; FVC: supplementary figures S2 and S3) (p-values for heterogeneity, obese *versus* non-obese: p=0.098 for NO~2~/FEV~1~ (figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}); p=0.026 for NO~2~/FVC (supplementary figures S2 and S3); p=0.050 for NO~x~/FVC). All other tested factors (sex, smoking and asthma status) showed no or only weak evidence for modification of the air pollution lung function associations (NO~2~: supplementary table S8). The effect modification by obesity was also evident in sex-stratified analyses, with substantially stronger inverse NO~2~ and NO~x~ associations with FEV~1~ and FVC, in both obese females and males (NO~2~: supplementary table S9).

![Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO~2~ with level of forced expiratory volume in 1 s (FEV~1~; in mL) in participants stratified as not obese (body mass index (BMI) \<30 kg·m^−2^). NO2_1 indicates NO~2~ measured at time of ESCAPE. Associations with lung function measures are presented as increments in NO~2~ per 10 μg·m^−3^. I-square: variation in estimated effects attributable to heterogeneity. D+L (Der Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were adjusted for: age, age squared, height, sex, BMI, highest educational level, and smoking status at second spirometry; negative estimates indicated lower lung function with increasing exposure. p-value for heterogeneity, obese *versus* non-obese: 0.098 for FEV~1~. ES: effect size.](ERJ-01300-2014.03){#F3}

![Forest plot displaying the study-specific mixed linear regression model estimates of the association of NO~2~ with level of forced expiratory volume in 1 s (FEV~1~; in mL) in obese participants (body mass index (BMI) ≥30 kg·m^−2^). NO~2~\_1 indicates NO~2~ measured at time of ESCAPE. Associations with lung function measures are presented as increments in NO~2~ per 10 μg·m^−3^. I-square: variation in estimated effects attributable to heterogeneity. D+L (Der Simonian and Laird method): pooled estimate of all studies. The mixed linear regression models were adjusted for: age, age squared, height, sex, BMI, highest educational level, and smoking status at second spirometry; negative estimates indicated lower lung function with increasing exposure. p-value for heterogeneity, obese *versus* non-obese: 0.098 for FEV~1~. ES: effect size.](ERJ-01300-2014.04){#F4}

In sensitivity analysis, looking at non-movers and participants aged 30 years or more, we did not find a particular difference from the observed main associations (supplementary table S10).

Discussion {#s4}
==========

This study in adults contributes to the evidence of long-term exposure to ambient air pollution being associated with the level of lung function. The meta-analysis was based on individual-level exposure assessment standardised across different cities and regions in Europe. Impaired lung function characterised by reduced FEV~1~, a powerful marker of future morbidity and mortality \[[@C16]\], exhibited the most consistent association with different pollution metrics. It was inversely related to nitrogen oxides and PM~10~, as well as to traffic load at the residential address. Our data suggest that obese persons are particularly sensitive to air pollution.

Comparison with other studies {#s4a}
-----------------------------

Results from previous cross-sectional studies predominantly relied on exposure measured at the level of a few communities. They point to an inverse association of adult lung function with air pollution and traffic load \[[@C1], [@C6]\], but as the measurement and meaning of specific pollution metrics differs between studies their comparative relevance remains inconclusive. This also applies to the current study. According to the site-specific differences in correlations between exposure metrics (supplementary table S6) they capture different sources of air pollution and thereby different components. The absence of associations with most of the PM metrics may additionally be rooted in the more limited sample size. PM measurements were only performed in a limited number of centres. NO~2~, which characterises the spatial variation of traffic related air pollution, has been linked with stronger lung function impairment depending on the parameter studied, but evidence that PM effects are stronger has also been published \[[@C3], [@C7]\].

The interaction between air pollution exposure and obesity on lung function parallels a recent SAPALDIA report and adds evidence to the interdependence of the two important global epidemics of environmental pollution and obesity \[[@C17]\]. Many studies have demonstrated an association between obesity and lung function. Lung function improves after weight loss in obese persons, and weight gain is associated with lung function decline in asthmatics and in the general population \[[@C17]--[@C19]\]. The mechanical effect of excess body fat on lung volumes and airway calibre is well accepted \[[@C18]\]. In addition, inflammatory pathways may play a role, as overweight is associated with an underlying state of oxidative stress and inflammation \[[@C17], [@C20]\]. Air pollution and obesity seemingly have more than additive effects on systemic inflammation \[[@C21], [@C22]\]. In animal models, ozone-induced pulmonary injury and inflammation were greater in obese *versus* lean mice \[[@C23], [@C24]\]. In humans, acute ozone effects on lung function were more prominent among obese subjects \[[@C25], [@C26]\].

The null finding investigating the association of air pollution with the change in lung function is consistent with a previous report from the ECRHS cohort \[[@C27]\], but extends the finding to older cohorts. In light of the positive findings for the cross-sectional associations, this null finding may be surprising. Cross-sectional differences are expected to result at least in part from differences in age-related decline. Based on the current results it seems premature to conclude that long-term exposure to air pollution does not affect FEV~1~ and FVC decline.

Strengths and weaknesses {#s4b}
------------------------

Our study benefits from a large number of observations, and the multicentre design across different European regions, covering a broad range of different types of environment and climates and a wide age range of participants. Furthermore, the individual-level exposure assessment was harmonised, a common study protocol of exposure and outcome definition was developed and the analytic approach was standardised. However, this study has also several limitations.

Several methodological issues related to outcome and exposure assessment may have biased the longitudinal association. Data from only two spirometry time points and from spirometries conducted in different seasons and times of the day may have decreased the precision in estimating lung function decline. As common in long-term lung function studies, spirometry devices had to be updated with new software or replaced during follow-up. Such changes can be an inherent source of differences in the measured lung function and its temporal change \[[@C28]\]. The inherent limitations in exposure assessment are also amplified in the longitudinal analyses. Most importantly, back-extrapolation of residential pollution levels is of prime relevance to properly characterise exposure at first spirometry, and then derive the change in exposure over time. Uncertainties with the back-extrapolated values may be substantial and if unrelated to the true exposure, may bias findings towards the null. In addition LUR models have inherent limitations. Cross-validation of the LURs varied across regions \[[@C10], [@C11]\] and performance of models based on 20 or 40 measurement sites may be overestimated \[[@C29], [@C30]\].

Additional limitations of the study beyond back-extrapolation include the non-availability of information on short-term exposure at the time of spirometry for a sufficient number of sites and pollution metrics. Adjustment for short-term exposure in SAPALDIA did not alter the associations. Heterogeneity of study populations poses a challenge to meta-analysis and makes it difficult to exclude residual confounding and unrecognised effect modification. The associations were not sensitive to the SALIA study consisting exclusively of females and exhibiting the lowest mean levels of lung function (supplementary figures S4 and S5 for associations of NO~2~ with FEV~1~ and FVC in females). Non-participation at follow-up of subjects with low lung function may bias observed associations or limit their generalisability. In SAPALDIA, subjects with better lung function were more likely to participate in the second spirometry, but sensitivity analyses using inverse probability weighting to account for non-participation did not alter associations between air pollution and lung function \[[@C8]\].

Conclusion {#s4c}
----------

The current study, which includes a large number of observations from different regions, environments and climates in Europe, and standardized exposure assessment, provides firm support to an adverse association between ambient air pollution and lung function in adults. Inverse associations could be observed at very low air pollution levels in Europe. The policy relevance of these findings is further strengthened by the observation that obese persons may be particularly susceptible.
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